| Literature DB >> 8953683 |
B Brismar1, J E Akerlund, S Sjöstedt, C Johansson, A Törnqvist, B Bäckstrand, H Bång, L Andåker, P O Gustafsson, N Darle, M Angerås, A Falk, G Tunevall, B Kasholm-Tengve, T Skau, P O Nyström, T Gasslander, A Hagelbäck, B Olsson-Liljequist, A E Eklund, C E Nord.
Abstract
118 patients with complicated intra-abdominal infections participated in an open randomized comparative multicenter trial in order to compare the clinical and microbiological efficacy and safety of biapenem with imipenem/cilastatin (Tienam). 31 men and 27 women (mean age 52.3 years) were enrolled in the biapenem group, and 43 men and 17 women (mean age 52.3 years) in the imipenem/cilastatin group. The patients received either biapenem 500 mg every 8 h or imipenem/cilastatin 500 mg/500 mg every 6 h by intravenous infusion for up to 13 days (mean 6.5 days). 28/43 evaluable patients (65.1%) receiving biapenem and 27/40 evaluable patients (67.5%) in the imipenem/cilastatin group were clinically cured. The microbiological response was satisfactory in 28/43 evaluable patients (65.1%) receiving biapenem and in 27/40 evaluable patients (67.5%) receiving imipenem/cilastatin. No significant differences in clinical or microbiological efficacy between the two treatment groups were found. The present study shows that biapenem may be useful in the treatment of intra-abdominal infections.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8953683 DOI： 10.3109/00365549609037949
Source DB: PubMed Journal: Scand J Infect Dis ISSN： 0036-5548